Suven Life Sciences Ltd. share price target and research reports

Name: Latest research reports of Suven Life Sciences Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Suven Life Sciences Ltd.
Rating: 3
Author: Karvy

Latest analyst research reports with target prices and PDF download for SUVEN, BSE:530239 Suven Life Sciences Ltd.

Suven Life Sciences Ltd.

15 Jan 2018

208.22

-2.68%

Suven Life Sciences

Mgmt Note: Suven Life Sciences Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research We met the management of Suven Life Sciences (Suven) to understand the business model and its future plans. The company offers new chemical (NCE) based contract research & manufacturing services (CRAMS) across the value chain in drug discovery, development, manufacturing and support services in collaboration with leading global life science players. The company generated ~94% of its revenues in H1FY18 from NCE CRAMS business and the rest from technical services....

Suven Life Sciences Ltd. has lost -23.55% in the last 1 Month

Suven Life Sciences Ltd.

27 May 2015

208.22

-2.68%

Suven Life Sciences: Q4FY15 Results First Cut - Normalized Quarterly Revenues an... (May 27, 2015)

Suven Life Sciences Ltd.

Karvy

The revenue decline of 14% on QoQ basis and 15% on YoY basis was on expected lines on account of absence of prelaunch supplies last year and high value product mix in the last quarter. The same also impacted the asset utilization of the company impacting the margins in Q4FY15 compared to earlier periods.

Suven Life Sciences Ltd. is trading below its 30 day SMA of 252.7

Suven Life Sciences Ltd.

08 Mar 2015

208.22

-2.68%

Suven Life Sciences Initiation Report - Robust Base in CRAMS developing Offshoot... (Mar 08, 2015)

Hold: Suven Life Sciences Ltd.

Karvy

Karvy initiates the coverage on Suven Life Sciences with a HOLD recommendation. The company's base business of CRAMS is developing with additional segments, which are expected to drive revenue growth with comparable margin performance. The NCE development of the company is progressing at the pre-determined pace.

Suven Life Sciences Ltd. has gained 45.96% in the last 1 Year

Is Suven Life Sciences Ltd. worth buying?

393 Votes:

Buy 80.41%

Sell 13.23%

Hold 6.36%